Home Sectors Healthcare Present Valuation: Eagle Pharmaceuticals (NASDAQ: EGRX)

Present Valuation: Eagle Pharmaceuticals (NASDAQ: EGRX)

7
0
SHARE

Eagle Pharmaceuticals is part of the healthcare sector and is in the drug manufacturers industry. The company CEO is Scott L. Tarriff. Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology.

Previous Intraday Trading Performance:

The EGRX stock showed a previous change of -4.27% with an open at 49.08 and a close of 47.13. It reached an intraday high of 49.57 and a low of 46.38.

Business Wire:  Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)

Liquidity:

The stock has a market cap of $702.9m with 14.9m shares outstanding, of which the float is 13.3m shares. Trading volume reached 706,954 shares compared to its average volume of 346,009 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Eagle Pharmaceuticals shares returned -5.40% and in the past 30 trading days it returned -19.06%. Over three months, it changed -31.33%. In one year it has changed -18.76% and within that year its 52-week high was 85.66 and its 52-week low was 46.38. EGRX stock is 1.62% above its 52 Week Low.

Our calculations show a 200 day moving average of 64.29 and a 50 day moving average of 56.66. Currently EGRX stock is trading -26.69% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

Business Wire:  Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)

Earnings:

The last annual fiscal EPS for the company was reported at 3.27 that ended on 31st of December 2017, which according to the previous close, that is a PE of 14.41. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.91. The TTM EPS is 2.09, which comes to a TTM PE of 22.55.

The following are the last four quarter reported earnings per share:
09-30-2018:  0.91
06-30-2018:  0.17
03-31-2018:  0.17
12-31-2017:  0.84

Base on our calculations, the intrinsic value per share is 67.84, which means it is possibly undervalued and has a margin of safety of 30.53%

Indicators to Watch:

Based on the latest filings, there is 151.40% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.70

SeekingAlpha:  Depomed beats by $0.03, misses on revenue

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 15.63%, return on assets is 10.66%, profit margin is 13.54%, price-to-sales is 3.60 and price-to-book is 3.62.

Company Scores:

All scores are out of six:
 3  :Valuation Score
 3  :Past Performance Score
 5  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.

LEAVE A REPLY

Please enter your comment!
Please enter your name here